Clinical Trials Logo

Clinically Isolated Syndrome clinical trials

View clinical trials related to Clinically Isolated Syndrome.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05277740 Recruiting - Clinical trials for Relapsing Remitting Multiple Sclerosis

Implementation of a Novel Functional Eye-Tracking Biomarker for Multiple Sclerosis

Start date: September 1, 2022
Phase:
Study type: Observational

This study aims to develop and validate a sensitive and non-invasive eye-tracking software application. This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by CIS and RRMS and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. The study data will be used to develop machine learning algorithms and validate a software application intended to identify which metrics-or combination thereof-can serve as reliable biomarker of CIS and RRMS disease progression and cognitive status.

NCT ID: NCT05204459 Recruiting - Multiple Sclerosis Clinical Trials

MS-ResearchBiomarkerS

MS-ReBS
Start date: November 11, 2021
Phase:
Study type: Observational

This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD). The primary goal is to assess whether combining information from visual assessment, blood markers, as well as historical and ongoing longitudinal MRIs of the brain, orbit (the part of the skull where eyes are located), and/or spinal cord can predict changes in quantitative disability measures related to MSRD and neurological disease.

NCT ID: NCT05154370 Recruiting - Multiple Sclerosis Clinical Trials

China National Registry of Neuro-Inflammatory Diseases

CNRID
Start date: December 15, 2021
Phase:
Study type: Observational

Central nervous system (CNS) idiopathic inflammatory demyelinating diseases (IDD) are mainly diseases caused by autoimmune factors that result in CNS demyelination damage and loss. It tends to accumulate in the brain, spinal cord and optic nerves. Multiple sclerosis (MS), clinically isolated syndrome (CIS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and acute disseminated encephalomyelitis (ADEM) are all common IDDs of the CNS. Besides, primary angiitis of the central nervous system (PACNS), autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A), etc. may also be included because they are important differential diagnoses. This study will establish a large prospective cohort study database of Chinese IDD, which will record detailed electronic information on IDD patients, including demographic and socioeconomic data, medical history, clinical information, medication, and relevant examination results. The long-term observational study will be used to understand the natural history of disease, disability progression rates, imaging and biological indicators, long-term treatment approaches and prognosis of Chinese patients with IDD, to find predictive markers for IDD progression and prognosis, and to identify factors that influence the treatment and prognosis of patients with IDD.

NCT ID: NCT05057676 Recruiting - Multiple Sclerosis Clinical Trials

Autoimmune Intervention Mastery Course Study

AIM
Start date: December 1, 2021
Phase: N/A
Study type: Interventional

The goal of this project is to critically evaluate the effectiveness of using an online program to improve diet and self-care in patients with multiple sclerosis (MS), clinically isolated syndrome (CIS), fibromyalgia, and post acute sequela of covid

NCT ID: NCT04798651 Recruiting - Multiple Sclerosis Clinical Trials

Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis

T4MS
Start date: September 30, 2021
Phase: N/A
Study type: Interventional

The study aims at identifying the type of B and CD4 T cell subsets with pathogenic properties in the different clinical forms of multiple sclerosis. This research might open new therapeutic approaches for the treatment of multiple sclerosis particularly progressive MS.

NCT ID: NCT03979391 Recruiting - Clinical trials for Clinically Isolated Syndrome

Isoelectric Focusing of Tears in Children With Radiologically Isolated or Clinically Isolated Syndrome

OBIT
Start date: September 26, 2019
Phase: N/A
Study type: Interventional

The main gold of this study is to lead a multicentric, prospective study, to evaluate the diagnostic quality of tears in children with clinically isolated syndrome (CIS) and radiologically isolated syndrome (RIS) during a longitudinal follow-up.

NCT ID: NCT03610139 Recruiting - Multiple Sclerosis Clinical Trials

Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients

Start date: May 21, 2018
Phase: N/A
Study type: Interventional

This is a longitudinal single blind randomized trial to test the effects of high compared to low dose vitamin D3 supplementation on cognitive performance at 6 and 12 months, and MRI measures of 12 months duration. A cognitive assessment battery will be administered at baseline, 6 and 12 months. Related clinical data and information on depression and anxiety, lifestyle, and food sources of vitamin D and sun exposure among other variables will also be collected.

NCT ID: NCT03586986 Recruiting - Multiple Sclerosis Clinical Trials

Risk Factors in Early Multiple Sclerosis

RISEMS
Start date: July 26, 2018
Phase:
Study type: Observational

The central hypothesis of this protocol is that it is possible, using First Degree Relatives (FDRs) of patients with Multiple Sclerosis (MS) and assessing a variety of both known and unknown risk factors for MS, to define a risk algorithm for earliest signs of development of MS. The plan will be to do an abbreviated brain Magnetic Resonance Imaging (MRI) scan in asymptomatic, young FDRs, analyze blood for a variety of immunological, genetic, neuroaxonal damage, metabolic, viral serology and other markers, and have FDRs fill out a detailed bioscreen questionnaire about lifestyle factors and perform a cognitive screening test. The investigators will then compare the results of the various blood/other studies in FDRs with and without an MRI showing signs signs concerning for MS, as well as age-and sex-matched NON-FDRs who will have blood drawn and fill out the questionnaire. With this preliminary cross-sectional study, the investigators hope to begin to identify a risk stratification model for those at highest risk of developing MS, ie FDRs, with a long-term goal of developing a longitudinal study to increase sensitivity and specificity of the risk model.

NCT ID: NCT03541226 Recruiting - Multiple Sclerosis Clinical Trials

Clinical Monitoring, MRI and Neuro-Ophthalmology of a Cohort of Patients With a Clinically Isolated Syndrome (CIS)

cinocis
Start date: September 2014
Phase:
Study type: Observational

The purpose of this study is to develop tools to detect, measure, monitor and predict axonal damage in the course of CIS and during Multiple sclerosis (MS), in order to be able to consider as early as possible an adaptation of the background treatment in patients with MS. patients with radiological criteria of poor long-term clinical course.

NCT ID: NCT03004079 Recruiting - Clinical trials for Relapsing Remitting Multiple Sclerosis

Clinical Importance of Glucose Regulation in Relapsing MS

Start date: October 2016
Phase:
Study type: Observational

The purpose of this study is to assess the relationship of blood glucose levels in persons with Multiple Sclerosis (MS) who have experienced a relapse and will be receiving intravenous steroids for the relapse, to their recovery from the relapse. Steroid exposure commonly leads to elevated serum blood glucose, however, standardized monitoring of blood glucose levels in the outpatient setting is not common. The clinical impact of any associated elevated blood glucose during steroid administration is unknown. We hypothesize that the blood glucose response to steroid treatment is clinically relevant to the MS-relapse recovery.